Abstract
Background Identifying optimal COVID-19 policies is challenging. For the state of Victoria, Australia (6.6 million people), we ranked 44 policy packages: two levels of stringency of public health and social measures (PHSMs); the provision of respirators during infection surges; and 11 vaccination schedules (including current and next-generation COVID-19 vaccines) in the context of 64 potential future SARS-CoV-2 variants (combinations of transmissibility, virulence, immune escape capacity and incursion date).
Methods We used an agent-based model to estimate morbidity, mortality, and costs over an 18-month period beginning 1 April 2022 for each scenario. Policy options were ranked on cost-effectiveness (health system only and health system plus GDP perspectives), deaths and days exceeding hospital occupancy thresholds.
Results The median number of infections across the 44 policies was 6.2 million (range of medians 5.4 to 7.1 million). Higher stringency PHSMs ranked better from a health system perspective, but not a health system plus GDP perspective. The provision of respirators had minimal impact. Vaccinating all age groups was superior to both no further vaccination and targeted vaccination of individuals aged ≥60 years. The optimal combined policy was the rollout of a multivalent vaccine to all age groups with higher stringency PHSMs and no respirator provision.
Conclusions This integrated epidemiologic and economic model provides a framework within which to systematically compare the health and economic benefits and costs of pandemic interventions while accounting for SARS-CoV-2 evolution and dynamic population immunity. It underscores the value of ongoing widespread vaccination and PHSMs in mitigating future COVID-19-related morbidity and mortality.
Competing Interest Statement
Our study was funded by an anonymous philanthropic donation to the University of Melbourne. Outside of the current study, we will soon receive funding from Moderna to conduct vaccine effectiveness studies in Australia. We wish to emphasize that Moderna had no role whatsoever in the current study.
Funding Statement
Funding: an anonymous philanthropic donation and strategic University of Melbourne funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: an anonymous philanthropic donation and strategic University of Melbourne funding.
Data Availability
Data produced in the present study may be available upon reasonable request to the authors
